Fig. 4.

Inhibition of DOT1L leads to increased sensitivity to PARP inhibition. a, d Cell proliferation of SW837 (a) and U2OS (d) cells treated either with IRI (1 μM), EPZ (1 μM), or Veliparib (VEL) individually or in combination and measured every 24 h using the Celigo cytometer. b, e Bar graph representation of cell proliferation of SW837 cells from a at day 10 and U2OS cells from D at day 7. Data are represented as mean values n = 3, ± SD, and p value (b *0.01, *0.03, ***0.0001; e **0.002). c, f Western blot analysis from SW837 (c) and U2OS (f) cells treated as in (a, d) after 48 h of treatment. Total protein lysates were harvested and analyzed by Western blot using antibodies against the indicated proteins